BioNTech to set up mRNA manufacturing hubs in Australia
BioNTech, co-developers of one of the first mRNA COVID-19 vaccines, have signed an agreement to create manufacturing hubs in and around the Australian Victoria state in a bid to increase the country’s mRNA manufacturing abilities.
Germany biotechnology company BioNTech SE (Mainz, Germany), developers of the widely utilised COVID-19 mRNA vaccine with Pfizer, have confirmed their partnership with Australia’s Victoria state to set up mRNA research and manufacturing centres in the area.
The partnership will also see the creation of a centre that will run clinical research on experimental mRNA vaccines and therapeutics, with the intention of attracting scientific experts from around the world. It was also agreed that an mRNA manufacturing facility will be set up in Melbourne.
The announcement comes on the heels of Australia’s initial immunisation program, which was marred by import delays leading to political backlash. The government has since been pressured to invest in domestic mRNA vaccine manufacturing facilities to ease supply chain challenges. Victorian Minister for Innovation, Medical Research, and the Digital Economy Jaala Pulford stated: “The state-of-the-art facility is the missing link in our mRNA ecosystem, and it means Victorians can be the first in the world to potentially receive new vaccines and treatments for oncology and infectious diseases.”
Victoria had previously signed a deal with Moderna (Cambridge, USA) for the construction of an mRNA manufacturing facility at Monash University (Melbourne, Australia), making the BioNTech deal the second to be signed for Australia in a bid to increase the country’s domestic mRNA manufacturing capabilities.
BioNTech CEO Ugur Sahin commented that science was only effective when applied “outside of the laboratories and reaches people worldwide... This partnership is a major step forward to enable access to mRNA technology and promote collaborations in the Asia–Pacific region.”
Source: German COVID vaccine developer BioNTech signs research deal with Australia | Reuters
Related News
-
News Women in Pharma: Moving beyond discussions and into best practice at CPHI Milan
In this second CPHI Milan special of our monthly series, we cover the key takeaways from the Diversity & Wellbeing track held on October 10, 2024. -
News AstraZeneca invests in AI collaboration for cancer drug trials
The British-Swedish pharmaceutical giant is partnering with biotechnology firm Immunai Inc to increase the efficiency of some cancer drug trials. -
News Ozempic and Wegovy prices questioned as Novo Nordisk faces US Senate hearing
The CEO of Novo Nordisk was grilled during a US Senate committee hearing on September 24, 2024, in which the exorbitant prices of the Danish company’s blockbuster drugs Ozempic and Wegovy were called into question. -
News The BIOSECURE Act: implications for the pharma supply chain
On September 9, 2024, the US House of Representatives voted to pass the bill titled the BIOSECURE Act (the Act), which lists several Chinese companies in the pharmaceutical supply chain. The Act will prohibit American companies from contracting or doin... -
News On Track at CPHI Milan: Thermo Fisher Scientific Track Sponsor interview
With CPHI Milan just around the corner, we sat down with some of the sponsors for this year’s conference tracks to discuss the most pressing topics in pharma. -
News CPHI Milan Speaker Spotlight: Pharma Manufacturing and Localisation in Africa
In the run-up to CPHI Milan, we sit down with some of the experts and thought-leaders speaking at this year’s conferences. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Eli Lilly licenses rheumatoid arthritis manufacturing in Africa
American pharmaceutical company Eli Lilly has signed a partnership with Egyptian organisation Eva Pharma to localise manufacturing of rheumatoid arthritis treatments in Africa.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance